Douglas Thorburn News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Douglas thorburn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Douglas Thorburn Today - Breaking & Trending Today

Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis

Includes Extensive Data Showing that CM-101, Chemomab s CCL24-Neutralizing Antibody, Interrupts the Fibro-Inflammatory Processes that Lead to PSC
TEL AVIV, Israel, June 28, 2023 /PRNewswire/ Chemomab Therapeutics Ltd. (Nasdaq: CMMB), . ....

City Of , United Kingdom , Irina Koffler , Barbara Lindheim , Douglas Thorburn , Wadi Mor , Prnewswire Chemomab Therapeutics Ltd , Digestive Health Division , Chemomab Therapeutics Ltd , Lifesci Advisors , Digestive Health , Strategic Communications , Institute Of Liver , Includes Extensive Data Showing , Neutralizing Antibody , Fibro Inflammatory Processes , Divisional Medical Director , Royal Free London , Principal Investigator , Private Securities Litigation Reform , Vice President , Sci Advisors ,

Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023

/PRNewswire/ Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare. ....

Barbara Lindheim , Wadi Mor , Raanan Greenman , Rifaat Safadi , Avi Katav , John Lawler , Homer Levi , Douglas Thorburn , Chris Cirillo , Irina Koffler , Matthew Frankel , Shelia Sherlock , Tom Snir , Christopher Bowlus , Ilan Vaknin , Massimo Pinzani , Hepatology At University College London , Prnewswire Chemomab Therapeutics Ltd , Digestive Health , Institute For Liver , Data Monitoring Committee , Strategic Communications , Lifesci Advisors , Chemomab Therapeutics Ltd , New Proteomics Data Further Confirms , Sclerosing Cholangitis ,

Chemomab Announces First Patient Enrolled in Phase IIa Study of CM-101 for the Treatment of Patients with Primary Sclerosing Cholangitis

Share this article
Share this article
TEL AVIV, Israel, Feb. 2, 2021 /PRNewswire/ Chemomab Ltd., a clinical-stage biotech company focusing on discovery and development of innovative therapeutics for fibrosis-related diseases, today announces enrollment of the first patient in a phase IIa clinical trial of CM-101 for the treatment of patients with primary sclerosing cholangitis (PSC).
The SPRING phase IIa study is a multicenter, double-blind, placebo-controlled study designed to evaluate the safety and efficacy profile of CM-101 in adult subjects with PSC over 15 weeks of treatment. The study is being conducted at multiple leading sites in the United Kingdom and Israel, and will enroll up to 45 patients randomized in a 2:1 ratio between CM-101 and placebo. ....

City Of , United Kingdom , Peter Thiel , Anchiano Adss , Douglas Thorburn , Wadi Mor , Sharon Elkobi , Company Annual Report On Form , University College London , Prnewswire Chemomab Ltd , Institute For Liver Digestive Health , Anchiano Therapeutics Ltd , Chemomab Ltd , Business Development , Royal Free Hospital , Digestive Health , London United Kingdom , Primary Sclerosing Cholangitis , Anchiano Therapeutics , Information About , Investor Relations , Definitive Proxy Statement , Securities Act , Private Securities Litigation Reform , Annual Report , Quarterly Reports ,